Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Biocytogen just stacked two cancer bets in three days. Is its platform strategy starting to compound? Biocytogen’s NEOK002 IND clearance and Moonlight Bio deal highlight a platform-led oncology strategy. Read what it means for growth and sentiment. byVenkateshMarch 27, 2026